<!doctype html>
<html lang="en">
  <head>
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>NKTR Shares Surge 38.2% in a Week: Here&#x27;s What You Should Know</title>
    <meta name="description" content="Year to date, shares of Nektar have surged 188.1% compared with the industry’s rise of 14.1%.; The company expects to advance rezpeg into phase III development in the first half of 2026.; Shares of Nektar Therapeutics NKTR have rallied 38.2% in the past week due to growing investor optimism related to the company’s lead pipeline candidate, rezpegaldesleukin (rezpeg), which is being developed as a self-adm" />
    <link rel="alternate" type="application/rss+xml" title="Daily Finance Newsletter" href="https://suavir600.github.io/newsletter/feed.xml" />
    <style>
:root{--bg:#0b0f19;--fg:#e8ecf2;--muted:#93a1b1;--card:#121826;--accent:#4f8cff}
*{box-sizing:border-box} body{margin:0;background:var(--bg);color:var(--fg);font:16px/1.55 system-ui,-apple-system,Segoe UI,Roboto,Ubuntu}
a{color:var(--accent);text-decoration:none} a:hover{text-decoration:underline}
.container{max-width:980px;margin:0 auto;padding:20px}
.nav{display:flex;align-items:center;justify-content:space-between;margin-bottom:20px}
.brand{font-weight:700} .muted{color:var(--muted)}
.grid{display:grid;grid-template-columns:repeat(auto-fill,minmax(280px,1fr));gap:16px}
.card{background:var(--card);border-radius:16px;padding:16px;box-shadow:0 6px 20px rgba(0,0,0,.25)}
.card h3{margin:0 0 8px 0;font-size:1.05rem}
.badge{display:inline-block;background:#1c2335;color:#c0cad8;padding:.2rem .5rem;border-radius:999px;font-size:.75rem;margin-right:.4rem}
.btn{display:inline-block;background:var(--accent);color:#fff;padding:.5rem .75rem;border-radius:10px;font-weight:600}
.btn-outline{background:transparent;border:1px solid var(--accent);color:var(--accent)}
.list ul{margin:.5rem 0 0 1.2rem}
.footer{margin-top:36px;color:var(--muted);font-size:.9rem;text-align:center}
hr{border:none;border-top:1px solid #223; margin:16px 0}
</style>
  </head>
  <body>
    <div class="container">
      <div class="nav">
        <div class="brand"><a href="https://suavir600.github.io/newsletter">Daily Finance Newsletter</a></div>
        <div class="muted">5–7 key bullets per story</div>
      </div>
      
<h1>NKTR Shares Surge 38.2% in a Week: Here&#x27;s What You Should Know</h1>
<div class="muted">2025-09-08 15:27:00+00:00</div>
<hr />
<div class="list"><ul>
  <li>Year to date, shares of Nektar have surged 188.1% compared with the industry’s rise of 14.1%.</li><li>The company expects to advance rezpeg into phase III development in the first half of 2026.</li><li>Shares of Nektar Therapeutics NKTR have rallied 38.2% in the past week due to growing investor optimism related to the company’s lead pipeline candidate, rezpegaldesleukin (rezpeg), which is being developed as a self-adm</li><li>Image Source: Zacks Investment Research NKTR’s Atopic Dermatitis Data on Rezpeg In June 2025, NKTR announced that the phase IIb REZOLVE-AD study evaluating rezpeg in patients with moderate-to-severe atopic dermatitis met</li><li>Despite amlitelimab meeting all primary and key secondary endpoints in the COAST 1 study, shares of SNY tanked as the data seemed to fall short of investors&#x27; expectations.</li><li>Here’s Why NKTR Was Up This Past Week Nektar’s price rose after French drugmaker Sanofi SNY announced data from the phase III COAST 1 study evaluating its pipeline candidate, amlitelimab, for treating moderate-to-severe</li><li>However, rezpeg’s long-term efficacy is yet to be determined.</li>
</ul></div>
<div style="margin-top:12px">
  <a class="btn-outline" href="https://finance.yahoo.com/news/nktr-shares-surge-38-2-152700121.html" target="_blank" rel="noopener">Original</a>
  <a class="btn" href="https://twitter.com/intent/tweet?text=NKTR+Shares+Surge+38.2%25+in+a+Week%3A+Here%27s+What+You+Should+Know%0A%E2%80%A2+Year+to+date%2C+shares+of+Nektar+have+surged+188.1%25+compared+with+the+industry%E2%80%99s+rise+of+14.1%25.%0A%E2%80%A2+The+company+expects+to+advance+rezpeg+into+phase+III+development+in+the+first+half+of+2026.%0Ahttps%3A%2F%2Fsuavir600.github.io%2Fnewsletter%2Farticles%2Fnktr-shares-surge-38-2-in-a-week-here-s-what-you-should-know%2F" target="_blank" rel="noopener">Share on X</a>
</div>

      <div class="footer">© 2025 · Built from digest_5bullets.md</div>
    </div>
  </body>
</html>